Literature DB >> 21146220

The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity.

Yurong Li1, Jiannan Feng, Shaoxia Geng, Shusheng Geng, Huawei Wei, Guojiang Chen, Xinying Li, Liyan Wang, Renxi Wang, Hui Peng, Gencheng Han, Beifen Shen, Yan Li.   

Abstract

By binding to T cell Ig mucin-3 (Tim-3) expressed on different cells, galectin-9 (Gal-9) mediates two important functions, triggering T cell death and activating innate immune cells. The mechanisms by which ligation of the same molecule on different cell types mediates different effects are largely unclear. Gal-9 contains two carbohydrate recognition domains (CRD) in the N- and C-terminal regions (Gal-9-N and Gal-9-C). The N and C terminals of Gal-9 have been shown to have different activities in promoting T cell death. However, whether the differences between two domains account for its dual functions remains to be elucidated. Here we hypothesized that the different functions of Gal-9 in innate immunity and adaptive immunity are mediated by different domains. To test this, we created recombinant Gal-9 (Gal-9-NC) and homodimers containing either the NCRD (Gal-9-N) or the CCRD (Gal-9-C). All these Gal-9 constructs can activate dendritic cells (DCs) and induce T cell death. However, the Gal-9-C was much more potent than the Gal-9-N in inducing T cell death, while the Gal-9-N was much more effective in activating DCs by inducing much higher TNF-α and IL-6 production, greater phosphorylation of p38 and AKT. In both DC and T cells, Gal-9-N but not Gal-9-C stimulation resulted in markedly iκBα degradation. Finally, computer analyses suggested different patterns and affinities for the binding of the Gal-9-N and Gal-9-C to their receptor, Tim-3. Our data suggest that the N- and C-terminal CRDs of Gal-9 contribute differently to its ability to induce T cell death and to activate DCs. Further investigations on the underlying mechanisms will provide new insights into the biochemical basis for the multiple activities of Gal-9.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21146220     DOI: 10.1016/j.molimm.2010.11.011

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  18 in total

Review 1.  Galectin-9: Diverse roles in hepatic immune homeostasis and inflammation.

Authors:  Lucy Golden-Mason; Hugo R Rosen
Journal:  Hepatology       Date:  2017-05-27       Impact factor: 17.425

2.  Structural Basis for Carbohydrate Recognition and Anti-inflammatory Modulation by Gastrointestinal Nematode Parasite Toxascaris leonina Galectin.

Authors:  Eun Young Hwang; Mi Suk Jeong; Sang Kyun Park; Sung Chul Ha; Hak Sun Yu; Se Bok Jang
Journal:  J Biol Chem       Date:  2016-10-14       Impact factor: 5.157

3.  Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion.

Authors:  Pietro Bertino; Thomas A Premeaux; Tsuyoshi Fujita; Brien K Haun; Michael P Marciel; Fukun W Hoffmann; Alan Garcia; Haining Yiang; Sandra Pastorino; Michele Carbone; Toshiro Niki; John Berestecky; Peter R Hoffmann; Lishomwa C Ndhlovu
Journal:  Oncoimmunology       Date:  2019-04-17       Impact factor: 8.110

Review 4.  Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?

Authors:  Yuanwei Shi; Danting Tang; Xiaoqi Li; Xiaoli Xie; Yufu Ye; Lijuan Wang
Journal:  Front Oncol       Date:  2022-05-23       Impact factor: 5.738

5.  Blockade of the T cell immunoglobulin and mucin domain protein 3 pathway exacerbates sepsis-induced immune deviation and immunosuppression.

Authors:  Z Zhao; X Jiang; C Kang; Y Xiao; C Hou; J Yu; R Wang; H Xiao; T Zhou; Z Wen; J Feng; G Chen; Y Ma; B Shen; Y Li; G Han
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

6.  Galectin-9 inhibits TLR7-mediated autoimmunity in murine lupus models.

Authors:  Santosh K Panda; Valeria Facchinetti; Elisaveta Voynova; Shino Hanabuchi; Jodi L Karnell; Richard N Hanna; Roland Kolbeck; Miguel A Sanjuan; Rachel Ettinger; Yong-Jun Liu
Journal:  J Clin Invest       Date:  2018-04-03       Impact factor: 14.808

7.  Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations.

Authors:  Christopher Ungerer; Patricia Quade-Lyssy; Heinfried H Radeke; Reinhard Henschler; Christoph Königs; Ulrike Köhl; Erhard Seifried; Jörg Schüttrumpf
Journal:  Stem Cells Dev       Date:  2013-11-13       Impact factor: 3.272

Review 8.  Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma.

Authors:  María L Bacigalupo; Malena Manzi; Gabriel A Rabinovich; María F Troncoso
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

9.  Galectins as self/non-self recognition receptors in innate and adaptive immunity: an unresolved paradox.

Authors:  Gerardo R Vasta; Hafiz Ahmed; Mihai Nita-Lazar; Aditi Banerjee; Marta Pasek; Surekha Shridhar; Prasun Guha; José A Fernández-Robledo
Journal:  Front Immunol       Date:  2012-07-13       Impact factor: 7.561

Review 10.  Translational Implication of Galectin-9 in the Pathogenesis and Treatment of Viral Infection.

Authors:  Jenn-Haung Lai; Shue-Fen Luo; Mei-Yi Wang; Ling-Jun Ho
Journal:  Int J Mol Sci       Date:  2017-10-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.